|
| 37683132 | Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing. | JCO Oncol Pract | 2024 |
| 38019444 | A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. | Breast Cancer Res Treat | 2024 |
| 37839675 | Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow. | Mod Pathol | 2024 |
| 38052038 | Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. | Blood Adv | 2024 |
| 33491794 | Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion. | Am J Hematol | 2023 |
| 37556775 | Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. | J Clin Oncol | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 37693537 | Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy. | bioRxiv | 2023 |
| 38042922 | Post-diagnosis weight trajectories and mortality among women with breast cancer. | NPJ Breast Cancer | 2023 |
| 37976633 | Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study. | Eur J Cancer | 2023 |
| 37923752 | Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. | Nat Commun | 2023 |
| 36951169 | Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. | Cancer | 2023 |
| 37185922 | Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. | NPJ Breast Cancer | 2023 |
| 36990622 | Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. | Lancet Haematol | 2023 |
| 37451200 | Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. | Leuk Res | 2023 |
| 36945501 | Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. | medRxiv | 2023 |
| 37103927 | Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. | JAMA Oncol | 2023 |
| 37268724 | Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. | Nat Med | 2023 |
| 37099733 | Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. | JCO Precis Oncol | 2023 |
| 37267275 | Rekindling Joy in Medicine Through Thoughtful Communication: A Practical Guide. | Am Soc Clin Oncol Educ Book | 2023 |
| 37163357 | FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged â¿¥60 years. | Blood Adv | 2023 |
| 37356327 | Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. | Eur J Cancer | 2023 |
| 37194964 | Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. | J Am Coll Surg | 2023 |
| 36994212 | Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review. | Front Oncol | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 36521078 | Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. | J Clin Oncol | 2023 |
| 36401732 | The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HRâ¿¿+â¿¿/HER2â¿¿-) advanced/metastatic breast cancer. | Breast Cancer Res Treat | 2023 |
| 36583555 | Survival in male breast cancer over the past 3 decades. | J Natl Cancer Inst | 2023 |
| 36577290 | Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation. | Leuk Res | 2023 |
| 36534523 | Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. | Clin Cancer Res | 2023 |
| 36942937 | Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. | Oncologist | 2023 |
| 36564285 | Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. | Ann Oncol | 2023 |
| 36493334 | Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. | J Clin Oncol | 2023 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35941343 | Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. | Ann Surg Oncol | 2023 |
| 36074155 | Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. | Clin Cancer Res | 2023 |
| 36332187 | Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. | Blood | 2023 |
| 34326465 | Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. | Leukemia | 2022 |
| 35482127 | The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. | Breast Cancer Res Treat | 2022 |
| 35841843 | Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. | Eur J Cancer | 2022 |
| 35797509 | Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. | JCO Precis Oncol | 2022 |
| 35671420 | Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study. | JCO Oncol Pract | 2022 |
| 35538105 | A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. | NPJ Breast Cancer | 2022 |
| 35641483 | STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. | Nat Commun | 2022 |
| 35853853 | BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. | Blood Cancer J | 2022 |
| 35487836 | Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. | Ann Oncol | 2022 |
| 35658506 | Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 36450763 | Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). | NPJ Breast Cancer | 2022 |
| 36215125 | Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. | Clin Cancer Res | 2022 |
| 36069365 | Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. | Cancer | 2022 |